Combining a CDK4/6 inhibitor with hormone therapy before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests giving a CDK4/6 inhibitor (a drug that slows cancer growth) along with hormone therapy before breast cancer surgery. It aims to shrink tumors in people who couldn't complete or benefit from standard chemotherapy, offering a potential alternative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have early-stage (stage II or III) hormone receptor positive, HER2-negative breast cancer. HER2-negative means the cancer doesn't have too much of a protein that makes it grow fast.
- You haven't been able to finish or benefit from standard chemotherapy before surgery, either because it didn't work, you were too old, or you have other health conditions that make chemotherapy hard to tolerate.
- You are physically able to take care of yourself (ECOG score 0-2) and can swallow pills.
- You have not used a CDK4/6 inhibitor before and have no history of other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of CDK4/6 inhibitor pills (dalpiciclib vs. abemaciclib or ribociclib) taken after surgery for early-stage, hormone-positive, HER2-negative breast cancer. The goal is to see which is better tolerated and may help lower the risk of the cancer coming back.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
This study compares two hormone therapy approaches for advanced breast cancer that has returned after completing at least one year of a CDK4/6 inhibitor (like abemaciclib or ribociclib) taken with hormone therapy. It aims to see if a different hormone therapy combination works better than the doctor's choice of treatment.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new Breast Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.